PASADENA, Calif., Feb. 4, 2013 /PRNewswire/ -- CSNNewswire/Immunotech Laboratories, Inc. (PINKSHEETS:IMMB) Company Director Mr. Bo. Linton of Immunotech Laboratories, Inc, a Pasadena California based publicly traded company with patented "IPF" Technology today stated Immunotech's technology is now considered a major contender in the race for HIV & Cancer cures. Recent information provided by the company for clinical testing results in both the HIV and Cancer sectors for terminal (Salvage) patients showed the use of the company's patented "IPF" vaccine treatments significantly reduced the number of infected cells while leaving the non infected cells in tact, and almost immediately started the regeneration of the body's natural immune system. Mr. Linton further commented the company recently received an initial inquiry for a significant order of the company's patented HIV vaccine by an International associate for use as an "Experimental Drug". If confirmed the initial order would be in excess of several Million Dollars. This would expand the company's operations from Research & Development to a Bio-Pharma manufacturing company. In Africa, where approved experimental treatments are permitted, there are approximately 30 Million HIV/AIDS patients alone. About Immunotech Laboratories Immunotech Laboratories is a drug development company committed to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases such as HIV, Cancer, Hepatitis and AIDS. Immunotech is committed to creating drugs for the better health of mankind. Please visit Immunotechlab.com for information regarding the companies patented treatments, valuations and goals. Safe Harbor Statement: This news release contains forward-looking statements that involve risks and uncertainties associated with financial projections, budgets, milestone timelines, clinical development, regulatory approvals, and other risks described by Immunotech Laboratories, Inc. from time to time in its periodic reports filed with the SEC. IPF is not approved by the US Food and Drug Administration or by any comparable regulatory agencies elsewhere in the world. While Immunotech Laboratories believes that the forward-looking statements and underlying assumptions contained therein are reasonable, any of the assumptions could be inaccurate, including, but not limited to, the ability of Immunotech Laboratories to establish the efficacy of IPF in the treatment of any disease or health condition, the development of studies and strategies leading to commercialization of IPF in the United States, the obtaining of funding required to carry out the development plan, the completion of studies and tests on time or at all, and the successful outcome of such studies or tests. Therefore, there can be no assurance that the forward-looking statements included in this release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, Immunotech Laboratories or any other person that the objectives and plans of Immunotech Laboratories will be achieved should not regard the forward-looking statements as a representation. Immunotech Contact firstname.lastname@example.org Investor Relations:The Nabors Group: 713-875-9200E-mail: email@example.com/Naborsgroup SOURCE Immunotech Laboratories, Inc.